Kidney transplant drug switch aims to reduce Long-Term risks
NCT ID NCT00811915
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether switching kidney transplant patients from tacrolimus to sirolimus (both with mycophenolate mofetil) could reduce long-term complications like kidney damage, diabetes, and cancer. It involved 65 stable transplant recipients between 12 and 36 months after surgery. The trial was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sirolimus (Rapamune)
What this could lead to
If successful, switching to sirolimus could lower the risk of long-term kidney damage, new diabetes, and skin cancer after a kidney transplant.
What could go wrong
This trial was terminated early with only 65 participants, so results are limited. The switch may cause rejection or other side effects, and findings may not apply to all transplant patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UHAmiens
Amiens, France
-
UHAngers
Angers, 49933, France
-
UHCaen
Caen, 14000, France
-
UHLimoges
Limoges, France
-
UHNecker
Paris, 75015, France
-
UHRennes
Rennes, 35000, France
-
UHRouen
Rouen, 76000, France
-
UHTours
Tours, France